Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.
作者信息
Ganzel Chezi, Kharit Mira, Duksin Chen, Rowe Jacob M
机构信息
Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
出版信息
Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28.
Abstract
摘要
相似文献
1
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.达雷妥尤单抗治疗复发/难治性费城染色体阳性急性淋巴细胞白血病
Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28.
2
Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?费城染色体阴性成人急性淋巴细胞白血病首次完全缓解后异基因造血细胞移植的适应证：与微小残留病（MRD）有关的一切？
Bone Marrow Transplant. 2019 Jan;54(1):3-5. doi: 10.1038/s41409-018-0398-8. Epub 2018 Nov 16.
3
T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.富含T细胞的HLA单倍型相合造血干细胞移植治疗复发/难治性儿童费城染色体阳性急性淋巴细胞白血病且不进行移植后酪氨酸激酶抑制剂治疗
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26242. Epub 2016 Oct 26.
4
Philadelphia chromosome-positive acute lymphoblastic leukemia with an e14a3 BCR-ABL1 fusion: The role of molecular monitoring.伴有e14a3 BCR-ABL1融合的费城染色体阳性急性淋巴细胞白血病：分子监测的作用
Hematol Oncol Stem Cell Ther. 2020 Sep;13(3):166-167. doi: 10.1016/j.hemonc.2019.04.001. Epub 2019 May 28.
5
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病异基因造血细胞移植后复发的结果。
Am J Hematol. 2024 Aug;99(8):1636-1639. doi: 10.1002/ajh.27365. Epub 2024 May 27.
6
Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission.异基因造血干细胞移植前的主要分子反应可预测成人费城染色体阳性急性淋巴细胞白血病首次缓解期的更好预后。
Bone Marrow Transplant. 2017 Mar;52(3):470-472. doi: 10.1038/bmt.2016.307. Epub 2017 Jan 16.
7
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.异基因造血干细胞移植与酪氨酸激酶抑制剂联合化疗治疗费城染色体阳性急性淋巴细胞白血病。
Biol Blood Marrow Transplant. 2018 Apr;24(4):741-750. doi: 10.1016/j.bbmt.2017.12.777. Epub 2017 Dec 13.
8
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.复发或难治性费城染色体阳性急性淋巴细胞白血病患儿的挽救治疗
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26423. Epub 2017 Jan 13.
9
[Current treatment of philadelphia chromosome-positive acute lymphoblastic leukemia].[费城染色体阳性急性淋巴细胞白血病的当前治疗方法]
Rinsho Ketsueki. 2014 Oct;55(10):1972-80.
10
Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies.老年费城染色体阴性B细胞急性淋巴细胞白血病：当前治疗与新疗法
Best Pract Res Clin Haematol. 2017 Sep;30(3):184-192. doi: 10.1016/j.beha.2017.08.001. Epub 2017 Aug 3.
引用本文的文献
1
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant.达雷妥尤单抗与本妥昔单抗联合治疗对传统化疗和异基因干细胞移植难治的T细胞急性淋巴细胞白血病
Haematologica. 2024 Feb 1;109(2):689-692. doi: 10.3324/haematol.2023.283740.
2
CD38 as a pan-hematologic target for chimeric antigen receptor T cells.CD38 作为嵌合抗原受体 T 细胞的泛血液肿瘤靶点。
Blood Adv. 2023 Aug 22;7(16):4418-4430. doi: 10.1182/bloodadvances.2022007059.
3
Targeting CD38 in Neoplasms and Non-Cancer Diseases.针对肿瘤和非癌症疾病中的CD38
Cancers (Basel). 2022 Aug 28;14(17):4169. doi: 10.3390/cancers14174169.
4
A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.光明前景：免疫疗法治疗儿科 T 细胞恶性肿瘤。
Int J Mol Sci. 2022 Aug 2;23(15):8600. doi: 10.3390/ijms23158600.
5
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.维奈托克通过增强肿瘤细胞的吞噬作用来提高治疗性抗体在 B 细胞恶性肿瘤中的疗效。
Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364.
6
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.复发难治性急性淋巴细胞白血病中使用或不使用化疗的达雷妥尤单抗。一项回顾性观察性校园ALL研究。
Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
7
Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.接受达雷妥尤单抗治疗的复发难治性早期胸腺祖细胞急性淋巴细胞白血病患者的长期预后
Am J Blood Res. 2021 Oct 15;11(5):528-533. eCollection 2021.
8
Daratumumab: new indications revolving around "off-targets".达雷妥尤单抗：围绕“非靶向”的新适应症
Haematologica. 2021 Dec 1;106(12):3032-3033. doi: 10.3324/haematol.2021.279487.
9
Selection of new immunotherapy targets for NK/T cell lymphoma.NK/T细胞淋巴瘤新免疫治疗靶点的选择
Am J Transl Res. 2020 Nov 15;12(11):7034-7047. eCollection 2020.
10
Recent updates for antibody therapy for acute lymphoblastic leukemia.急性淋巴细胞白血病抗体治疗的最新进展
Exp Hematol Oncol. 2020 Nov 27;9(1):33. doi: 10.1186/s40164-020-00189-9.
本文引用的文献
1
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.达雷妥尤单抗治疗 T 细胞急性淋巴细胞白血病的临床前疗效。
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
2
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.
Zotero 插件